|
|
 |
|
Viewing report
|
|
|
|
Disease and Therapy Review: Hepatitis B
Timely Data Resources, Inc., Nov 2008, Pages: 10
The Hepatitis B Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatments. Dosing information is provided for Intron A, lamivudine, Hepsera, and Baraclude. General information is included on sales of Hepsera.
Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Langes Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.
Customers who bought this item also bought
Stakeholder Opinions: Hepatitis C - Small-molecule antivirals pave the way for triple therapy
Disease and Therapy Review: Hepatitis C
Commercial and Pipeline Insight: Hepatitis B
Opportunities Assessment for Hepatitis B Therapeutics Market in Indonesia
Gene Therapy - Technologies, Markets and Companies
Hepatitis C Virus and Therapeutics - Global Strategic Business Report
Disease & Therapy Review (DTR) Executive Market Summaries
Pipeline and Commercial Insight: Hepatitis C - High Unmet Need Drives Rapid Innovation
Hepatitis in China - Liver Let Die?
Oxford Handbook of Evolution in Health and Disease
Commercial Perspectives: Hepatitis B and C - The Chinese Way?
Treatment Algorithms 2002: Hepatitis B and C
|
|
|
|
